Mobile

A single center, randomized, partially blind, placebo controlled, crossover, single oral dose study to assess the effect of concomitant antacid (calcium carbonate) on the pharmacokinetics and pharmaco...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-004177-95

A single center, randomized, partially blind, placebo controlled, crossover, single oral dose study to assess the effect of concomitant antacid (calcium carbonate) on the pharmacokinetics and pharmacodynamics of SMC021 (0.8 mg salmon calcitonin/200 mg 5-CNAC) in healthy postmenopausal women

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine the effect of calcium carbonate / magnesium hydroxide on the pharmacokinetics and pharmacodynamics (decrease in serum CTX-I) of SMC021 (0.8 mg salmon calcitonin/200 mg 5- CNAC)

Critère d'inclusion

  • Osteoporosis, osteoarthritis

Liens